Replies to post #76148 on Biotech Values

[bridgeofsighs]

I thought the AMLN call was excellent and worth a listen for anyone thinking of buying some AMLN. I think AMLN has some good arguments separating Byetta from Liraglutide. I was stunned to hear that the liraglutide dose for humans is 100 fold larger then the dosing for Byetta to get the same efficacy in humans.
I have made more money on AMLN then any stock or options I have ever traded. I nailed it with a huge option trade after approval of Byetta and before the LAR data was released. I trace the beginning of their problems back to when they couldn't keep up with demand and had to stop taking on new patients they have never really recovered their footing. Like Dew said in an earlier post has any company struggled so much wit a successful drug as AMLN?